Rabbit Recombinant Monoclonal MMP9 antibody. Suitable for IHC-P, WB and reacts with Human samples. Cited in 108 publications.
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
IHC-P | IP | Flow Cyt | WB | ICC/IF | |
---|---|---|---|---|---|
Human | Tested | Not recommended | Not recommended | Tested | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes For unpurified use at 1/800. Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Select an associated product type
The protein expressed by gene MMP9 is a matrix metalloproteinase that plays an essential role in the local proteolysis of the extracellular matrix and in leukocyte migration. It cleaves KiSS1 at a Gly-|-Leu bond and processes NINJ1 to generate the Secreted ninjurin-1 form. Additionally, MMP9 cleaves type IV and type V collagen into large C-terminal three-quarter fragments and shorter N-terminal one-quarter fragments. It degrades fibronectin but not laminin or Pz-peptide. This supplementary information is collated from multiple sources and compiled automatically.
CLG4B, MMP9, Matrix metalloproteinase-9, MMP-9, 92 kDa gelatinase, 92 kDa type IV collagenase, Gelatinase B, GELB
Rabbit Recombinant Monoclonal MMP9 antibody. Suitable for IHC-P, WB and reacts with Human samples. Cited in 108 publications.
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
The MMP-9 protein also known as matrix metalloproteinase-9 or gelatinase B functions as an enzyme involved in the breakdown of extracellular matrix proteins. It consists of a zinc ion at its active site and facilitates the degradation of type IV and V collagens fibronectin and elastin. MMP-9 has a molecular weight of approximately 92 kDa and is expressed in a variety of tissues including the liver lungs and immune cells. This enzyme can exist in monomer and dimer forms with its activity regulated by tissue inhibitors of metalloproteinases (TIMPs).
Matrix metalloproteinase-9 profoundly influences tissue remodeling inflammation and angiogenesis. It does not form part of a larger protein complex but interacts closely with substrates in the extracellular matrix. MMP-9 plays important roles in processes such as embryogenesis reproduction and wound healing through the remodeling of surrounding tissues. The MMP-9 protein is often measured using assays like ELISA or analyzed via techniques such as Western blotting to determine its expression levels and activity in different biological contexts.
MMP-9 participates in the matrix metalloproteinase pathway and the NF-kB signaling pathway. These pathways are essential in orchestrating processes such as tissue remodeling and inflammatory responses. MMP-9 acts alongside other matrix metalloproteinases including MMP-2 and is regulated by factors like cytokines growth factors and hormones ensuring the precision of extracellular matrix degradation during physiological processes.
Matrix metalloproteinase-9 has associations with cancer invasion and metastasis as well as chronic inflammatory diseases like rheumatoid arthritis. In cancer upregulated MMP-9 expression aids tumor cells in breaching the basement membrane facilitating metastasis. The disorder-associated pathways often involve interactions with proteins like vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-beta). Understanding MMP-9's role in these conditions can contribute to developing targeted therapies that inhibit its activity potentially mitigating disease progression.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking buffer and concentration 5% NFDM/TBST
Diluting buffer and concentration 5% NFDM/TBST
The expression of MMP-9 can be stimulated by various agents, such as inflammatory cytokine, growth factor, and 12-O-tetradecanoylphorbol-13-acetate (TPA) (PMID:21047770, 28969043).
Treatment increasing the expression of MMP-9 is recommended when using this antibody.
All lanes: Western blot - Anti-MMP9 antibody [EP1255Y] (ab137867) at 1/1000 dilution
Lane 1: LoVo (Human colorectal adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 2: Huh7 (Human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg
Lane 3: MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 4: HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 5: Caco-2 (Human colorectal adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 6: A549 (Human lung carcinoma epithelial cell) serum starved overnight whole cell lysate at 20 µg
Lane 7: A549 (Human lung carcinoma epithelial cell) serum starved overnight, then treated with 80nM TPA for 24 hours whole cell lysate at 20 µg
Lane 8: MDA-MB-231 (Human breast adenocarcinoma epithelial cell) serum starved overnight whole cell lysate at 20 µg
Lane 9: MDA-MB-231 (Human breast adenocarcinoma epithelial cell) serum starved overnight, then treated with 200nM TPA for 24 hours whole cell lysate at 20 µg
Lane 10: HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 78 kDa
Observed band size: 84 kDa
Exposure time: 180s
Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
All lanes: Western blot - Anti-MMP9 antibody [EP1255Y] (ab137867) at 1/1000 dilution
All lanes: U937 cell lysate at 10 µg
All lanes: Peroxidase conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution
Predicted band size: 15 kDa, 78 kDa
Observed band size: 78 kDa
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue labelling MMP9 with unpurified ab137867 at 1/800. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Negative control using PBS instead of primary antibody. Counterstained with hematoxylin.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue labelling MMP9 with purified ab137867 at 1/1000. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Negative control using PBS instead of primary antibody. Counterstained with hematoxylin.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human lymphoma tissue labelling MMP9 with unpurified ab137867 at 1/100.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
MMP9 Western blot staining using rabbit Anti-MMP9 antibody
Western blot: Rabbit Monoclonal[EP1255Y] to MMP9 ab137867 staining at 1/1000 dilution, shown in green; Mouse anti GAPDH (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20,000 dilution, shown in magenta. A band was observed at 78 kDa in Wild-type A549 TPA-treated (80nM, 24h) cell lysates with no signal observed at this size in Wild-type A549 Vehicle Control TPA (0nM, 24h) cell line. To generate this image, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3pc Milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit 800CW & Goat anti-Mouse 680RD at 1/20,000 dilution.
All lanes: Western blot - Anti-MMP9 antibody [EP1255Y] (ab137867) at 1/1000 dilution
Lane 1: Wild-type A549 TPA-treated (80nM, 24h) at 20 µg
Lane 2: Wild-type A549 Vehicle Control TPA (0nM, 24h) at 20 µg
Lanes 3 - 4: Western blot - Human MMP9 knockout A549 cell line (ab286527) at 20 µg
Lane 5: Human Lung at 20 µg
Lane 6: MOLT-4 at 20 µg
All lanes: Goat anti-Rabbit 800CW & Goat anti-Mouse 680RD at 1/20000 dilution
Performed under reducing conditions.
Predicted band size: 78 kDa
Observed band size: 78 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com